6712.TWO Ever Supreme Bio Technology Co. Ltd
- Market cap
- TWD 14.5B
- P/E
- 29.4x
- P/B
- 5.23x
- ROE
- 15.8%
- Dividend yield
- 2.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6712.TWO undervalued?
Graham number6712.TWO trades 161.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ever Supreme Bio Technology Co. Ltd fundamental analysis
No fundamental analysis for Ever Supreme Bio Technology Co. Ltd yet.
Ever Supreme Bio Technology Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic…
Full company profileEver Supreme Bio Technology Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ever Supreme Bio Technology Co. Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 70.6M | 439M | 628M | 758M | 934M | 1.02B | 925M |
| Gross Profit | -17.9M | 245M | 415M | 485M | 660M | 721M | 724M |
| Operating Income | -137M | 397M | 265M | 623M | 466M | 439M | 418M |
| EBITDA | -105M | 433M | 300M | 656M | 492M | 548M | 562M |
| Net Income | -107M | 370M | 201M | 539M | 367M | 429M | 444M |
| EPS | -1.58 | 4.91 | 2.66 | 7.22 | 4.14 | 4.90 | 4.41 |
| Balance Sheet | |||||||
| Total Assets | 858M | 2.02B | 1.97B | 2.08B | 2.14B | 2.00B | 3.54B |
| Total Liabilities | 77.6M | 125M | 181M | 233M | 342M | 478M | 724M |
| Shareholders' Equity | 781M | 1.90B | 1.79B | 1.84B | 1.79B | 1.53B | 2.81B |
| Cash & Short-term Investments | 415M | 1.34B | 1.27B | 1.34B | 302M | 222M | 550M |
| Total Debt | 43.2M | 34.4M | 17.9M | 5.90M | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -138M | 136M | 319M | 422M | 440M | 536M | 766M |
| Capital Expenditure | 60.8M | 4.65M | 5.60M | 5.83M | 5.56M | 5.72M | 446K |
| Free Cash Flow | -199M | 131M | 314M | 416M | 435M | 531M | 765M |
| Ratios | |||||||
| ROE | -13.7% | 19.5% | 11.2% | 29.3% | 20.5% | 28.1% | 15.8% |
| ROA | -12.4% | 18.3% | 10.2% | 26.0% | 17.2% | 21.4% | 12.6% |
| Net Profit Margin | -151.3% | 84.2% | 32.0% | 71.1% | 39.3% | 42.2% | 48.0% |
| Debt to Equity | 0.06x | 0.02x | 0.01x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ever Supreme Bio Technology Co. Ltd dividends
- Dividend yield
- 2.81%
- Forward dividend
- 3.33 TWD
- Payout ratio
- 95.0%
- Ex-dividend date
- Apr 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 408M | 4.66 | 95.0% |
| 2024 | TWD 440M | 4.96 | 119.8% |
| 2023 | TWD 136M | 1.82 | 25.3% |
| 2022 | TWD 309M | 4.11 | 154.2% |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1050:1000 on May 14, 2026.
Who owns Ever Supreme Bio Technology Co. Ltd
- Insiders 30.60%
- Institutions 2.59%
- Public & others 66.82%
- Shares outstanding 100M
- Free float 72.5M
Ever Supreme Bio Technology Co. Ltd company profile
- Company name
- Ever Supreme Bio Technology Co. Ltd
- Ticker
- 6712.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 30, Keya Road, Taichung, Taiwan
- Phone
- 886 4 2325 2888
- Website
- ever-supreme.com.tw
About Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products and related businesses; and cell preparations and investment activities in biotechnology and medical industry businesses. Ever Supreme Bio Technology Co., Ltd was incorporated in 2016 and is based in Taichung, Taiwan.
Ever Supreme Bio Technology Co. Ltd management
1- Po-Ching LeeFinancial Manager